Magali Svrcek
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 41
- Colorectal Cancer Surgical Treatments 21
- Pancreatic and Hepatic Oncology Research 21
- Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment 21
-
- Genetic factors in colorectal cancer 41
- Cancer Research top 2%
-
- Gastric Cancer Management and Outcomes 32
-
- Colorectal and Anal Carcinomas 21
-
- Inflammatory Bowel Disease 18
- Co-authors
- Thierry AndréScott KopetzMichael J. OvermanHeinz‐Josef LenzBart NeynsRay McDermottEric Van CutsemSara Lonardi
- Partner nations
- FranceBelgiumUnited States
In The Last Decade
Magali Svrcek
125 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 3.2k
- Gastroenterology 450
- Pathology and Forensic Medicine 1.2k
- Cancer Research 822
- Pulmonary and Respiratory Medicine 1.2k
Countries citing papers authored by Magali Svrcek
This map shows the geographic impact of Magali Svrcek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magali Svrcek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magali Svrcek more than expected).
Fields of papers citing papers by Magali Svrcek
This network shows the impact of papers produced by Magali Svrcek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magali Svrcek. The network helps show where Magali Svrcek may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Magali Svrcek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 19 | |
| 9 | 2023 | 5 | |
| 10 | 2023 | 51 | |
| 11 | 2023 | 5 | |
| 12 | Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Studybreakdown → | 2022 | 220 |
| 13 | 2022 | 2 | |
| 14 | 2021 | 34 | |
| 15 | 2020 | 15 | |
| 16 | 2020 | 1 | |
| 17 | 2020 | 9 | |
| 18 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancerbreakdown → | 2018 | 1429 |
| 19 | Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Featuresbreakdown → | 2018 | 301 |
| 20 | 2016 | 7 |
About Magali Svrcek
Magali Svrcek is a scholar working on Gastroenterology, Oncology and Pathology and Forensic Medicine, having authored 132 papers that have together received 4.8k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (41 papers), Genetic factors in colorectal cancer (41 papers), Gastric Cancer Management and Outcomes (32 papers), Colorectal Cancer Surgical Treatments (21 papers), Pancreatic and Hepatic Oncology Research (21 papers), Colorectal and Anal Carcinomas (21 papers), Gastrointestinal Tumor Research and Treatment (21 papers) and Inflammatory Bowel Disease (18 papers). The work is most often cited by research in Oncology (3.2k citations), Gastroenterology (450 citations) and Pathology and Forensic Medicine (1.2k citations). Magali Svrcek has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include Thierry André, Scott Kopetz, Michael J. Overman, Heinz‐Josef Lenz, Bart Neyns, Ray McDermott, Eric Van Cutsem, Sara Lonardi, Michael B. Sawyer and Alain Hendlisz.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.